Bone marrow (aspirate/biopsy), lymph node biopsy and imaging studies are performed in subjects with progressive disease. However, 72% of the participants never use PET/CT, which does not seem to be related to th
After treatment completion, a bone marrow (BM) aspirate/biopsy was recommended per protocol in case the patient achieved a complete remission (CR). Outcomes The primary objective of the study was to compare the efficacy of early versus deferred FCR in Binet stage A patients at high risk for ...
In the first case of Hodgkin lymphoma diagnosed at 6 months, immunohistochemical staining for CD15 and CD30 on archival bone marrow biopsy demonstrated Reed-Sternberg cells before treatment initiation.22 In the second case of Hodgkin lymphoma diagnosed at 27 months, a PLCG2 A708V mutation was ...
Investigators only requested bone marrow biopsy and MRD measurements for those who achieved a clinical complete response, which included 69.0%, 81.0%, 86.9%, and 84.8%, of patients receiving chemoimmunotherapy, venetoclax/rituximab, venetoclax/obinutuzumab, and venetoclax/obin...
His beta-2-microglobulin is 3.8, so it is high, and his bone marrow biopsy shows diffuse infiltration by CLL. Anthony, what’s your impression of this case? Do you think this is a typical case? Is somewhat unusual case? What’s your thoughts?Anthony Mato, MD, MSCE: Well, I think ...
Investigators only requested bone marrow biopsy and MRD measurements for those who achieved a clinical complete response, which included 69.0%, 81.0%, 86.9%, and 84.8%, of patients receiving chemoimmunotherapy, venetoclax/rituximab, venetoclax/obinutuzumab, and venetoclax/obinutuzumab...
Two years after diagnosis a bone marrow biopsy revealed mature lymphocytes with 'focal lymphoid aggregates' consistent with at diagnosis of CLL or well-differentiated lymphocytic lymphoma. Between 2 and 6 years after diagnosis she was followed with the only physical finding noted being a very small...
Bone marrow biopsy revealed diffuse infiltration by CLL. What do you test for when you see a patient with newly diagnosed CLL who needs treatment? Prognostic testing is something that is a moving target in CLL. The way I like to think of it is that the tests are only as good...
a higher ibrutinib gene signature score in CAR+ T cells at time to maximum concentration was linked with increased probability of undetectable minimal residual disease in the bone marrow and in the peripheral blood regardless of treatment arm. When the ibrutinib score was higher in endogenous T cel...